エピソード

  • Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network

    Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
    2025/12/12

    Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    1 時間 43 分
  • HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach

    HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
    2025/12/10

    Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    1 時間 5 分
  • Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/11/10

    Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    21 分
  • Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/10/20

    Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    25 分
  • Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/09/14

    Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    23 分
  • Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases

    Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
    2025/08/22

    Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    58 分
  • Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/08/18

    Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    18 分
  • Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

    Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
    2025/08/08

    Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation.

    CME information and select publications here.

    続きを読む 一部表示
    59 分